Hahn NM, Powles T, Massard C, et al. Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma (UC). J Clin Oncol. 2017;35 (suppl; abstr 4525).
LORIS voorspelt respons op en overleving na behandeling met checkpointremmer
sep 2024 | Immuuntherapie